Testing a new drug for interstitial lung disease
Part of Lungs & breathing clinical trials.
This trial tests a new medicine called NCR101 for people with interstitial lung disease (a lung condition that causes scarring). It aims to see if the drug is safe and helps slow the disease. You may be able to join if your current treatments are stable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have been diagnosed with interstitial lung disease, confirmed by a lung scan in the last 6 months.
- If you take steroids or anti-fibrotic drugs (pirfenidone or nintedanib), your dose must be stable and you plan to stay on it during the trial.
- You are willing to avoid pregnancy (use non-hormonal birth control) for the trial and 6 months after.
- You cannot have had a severe allergic reaction to similar drugs or their ingredients.
- You must not have needed a ventilator or high-flow oxygen (more than 15 hours a day) in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a single inhaled dose of RJ026 in patients with interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF) or connective tissue disease-related ILD (CTD-ILD). It helps see how the drug moves through the body and if it's safe.
This trial tests a new inhaled medication called ICF004 in healthy Chinese adults to see if it is safe and how the body processes it. You can join if you are generally healthy and between 18 and 50 years old.
This trial tests a treatment for people with advanced non-small cell lung cancer who also have interstitial lung disease (a type of lung scarring). It aims to find out if the treatment is safe and effective for this specific group of patients.
This study is testing a new way to speed up the diagnosis of interstitial lung disease (a group of lung scarring conditions). If you have symptoms or scan findings that suggest ILD but haven't been fully diagnosed yet, this trial may help you get a faster, clearer answer.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
This trial tests a new medication called SC1011 taken twice a day, compared to a placebo, to see if it can help people with IPF. It is for patients who were diagnosed within the last 5 years and have moderate lung function.
Hear when a new Interstitial Lung Disease (ILD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.